SEP
DNA icon

Signature Equity Partners’s Ginkgo Bioworks DNA Stock Holding History

Signature Equity Partners’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29
Closed -$178 – 1604
2026
Q1 		$178 Hold
29
– – ﹤0.01% 1490
2025
Q4 		$241 Buy
+29
New +$312 ﹤0.01% 1621

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Signature Equity Partners's DNA Position: Q2 2026 in Review

Signature Equity Partners sold out of Ginkgo Bioworks (DNA) in Q2 2026, closing a stake of 29 shares — an estimated $178 sold.

Signature Equity Partners first reported a position in DNA in Q4 2025 and held it in 2 quarters. The position peaked at $241 in Q4 2025. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Signature Equity Partners reported no remaining Ginkgo Bioworks position as of Q2 2026 after selling out during the quarter.
  • Signature Equity Partners sold 29 Ginkgo Bioworks shares in Q2 2026, an estimated $178.
  • Signature Equity Partners first reported a position in Ginkgo Bioworks in Q4 2025 and held it in 2 quarters.
  • Signature Equity Partners's Ginkgo Bioworks position peaked at $241 in Q4 2025.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.